Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX – Research Report) and Biogen (BIIB ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB)

In a report released today, from Wells Fargo maintained a Hold rating on Biogen, with a price target of $190.00. In addition to Wells Fargo, Biogen...

Wells Fargo Reaffirms Their Hold Rating on Biogen (BIIB)

Jefferies analyst Andrew Tsai maintained a Buy rating on Biogen today and set a price target of $210.00. Tsai covers the Healthcare sector, focusin...

Jefferies Keeps Their Buy Rating on Biogen (BIIB)

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Study OverviewThis Phase 3 Biogen study, officially titled “An Open-Label ...

Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Study OverviewThis Phase 1 Biogen study, officially titled “A Phase 1, Ran...

Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy

Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen today and set a price target of $157.00. Amsellem covers the Healthcare sec...

Biogen (BIIB) Gets a Hold from Piper Sandler

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LENZ Therapeutics (LENZ – Research Report) and Bioge...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Biogen, with a price target of $189.00. Accord...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$179.09	-0.44%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$179.09	-0.4%	1.29M
3
4
5
6

BIIB

BIIB

No Data Available

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel